Connection

Hermes Florez to Diabetes Mellitus, Type 2

Back to Details
This is a "connection" page, showing publications Hermes Florez has written about Diabetes Mellitus, Type 2.
Hermes Florez
Connection Strength
6.357
Diabetes Mellitus, Type 2
  1. Differences in complications, cardiovascular risk factor, and diabetes management among participants enrolled at veterans affairs (VA) and non-VA medical centers in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE). Diabetes Res Clin Pract. 2022 Feb; 184:109188.
    View in: PubMed
    Score: 0.416
  2. Are Eating Disorders Risk Factors for Type 2 Diabetes? A Systematic Review and Meta-analysis. Curr Diab Rep. 2017 Nov 22; 17(12):138.
    View in: PubMed
    Score: 0.313
  3. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ. 2017 Jan 17; 356:i6505.
    View in: PubMed
    Score: 0.295
  4. A new angle for glp-1 receptor agonist: the medical economics argument. Editorial on: Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of the once-daily glp-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ 2015: 1-13 [Epub ahead of print]. J Med Econ. 2015; 18(12):1029-31.
    View in: PubMed
    Score: 0.269
  5. Weight loss and physical activity for disease prevention in obese older adults: an important role for lifestyle management. Curr Diab Rep. 2014 Oct; 14(10):539.
    View in: PubMed
    Score: 0.252
  6. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes Obes Metab. 2014 Apr; 16(4):326-33.
    View in: PubMed
    Score: 0.236
  7. Beyond the obesity paradox in diabetes: fitness, fatness, and mortality. JAMA. 2012 Aug 08; 308(6):619-20.
    View in: PubMed
    Score: 0.217
  8. Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial. J Gen Intern Med. 2012 Dec; 27(12):1594-601.
    View in: PubMed
    Score: 0.215
  9. Association of Baseline Characteristics With Insulin Sensitivity and ?-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. Diabetes Care. 2021 02; 44(2):340-349.
    View in: PubMed
    Score: 0.194
  10. Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program. BMJ Open Diabetes Res Care. 2020 12; 8(2).
    View in: PubMed
    Score: 0.193
  11. Telehealth-assisted care coordination of older veterans with type 2 diabetes lowers coronary heart disease risk despite clinical inertia. Diabetes Technol Ther. 2010 Dec; 12(12):995-1001.
    View in: PubMed
    Score: 0.193
  12. The Impact of Physical Activity on the Prevention of Type 2 Diabetes: Evidence and Lessons Learned From the Diabetes Prevention Program, a Long-Standing Clinical Trial Incorporating Subjective and Objective Activity Measures. Diabetes Care. 2021 01; 44(1):43-49.
    View in: PubMed
    Score: 0.192
  13. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat Genet. 2020 07; 52(7):680-691.
    View in: PubMed
    Score: 0.187
  14. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med. 2010 Mar; 122(2):112-20.
    View in: PubMed
    Score: 0.183
  15. Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. Diabetes Technol Ther. 2019 12; 21(12):682-690.
    View in: PubMed
    Score: 0.177
  16. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up. N Engl J Med. 2019 Jun 06; 380(23):2215-2224.
    View in: PubMed
    Score: 0.174
  17. Prevalence and associations of binge eating disorder in a multiethnic population with type 2 diabetes. Diabetes Care. 2006 Dec; 29(12):2760.
    View in: PubMed
    Score: 0.146
  18. Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. Atherosclerosis. 2006 Sep; 188(1):134-41.
    View in: PubMed
    Score: 0.136
  19. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Jun 04; 372(23):2197-206.
    View in: PubMed
    Score: 0.132
  20. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab. 2015 Apr; 100(4):1646-53.
    View in: PubMed
    Score: 0.129
  21. Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2021 10; 44(10):2286-2292.
    View in: PubMed
    Score: 0.101
  22. Long-term effects of lifestyle and metformin interventions in DPP on bone density. Osteoporos Int. 2021 Nov; 32(11):2279-2287.
    View in: PubMed
    Score: 0.100
  23. Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study. J Gerontol A Biol Sci Med Sci. 2021 04 30; 76(5):929-936.
    View in: PubMed
    Score: 0.099
  24. The cross-sectional association of renal dysfunction with tests of cognition in middle-aged adults with early type 2 diabetes: The GRADE Study. J Diabetes Complications. 2021 03; 35(3):107805.
    View in: PubMed
    Score: 0.096
  25. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care. 2020 05; 43(5):940-947.
    View in: PubMed
    Score: 0.092
  26. Suitable Use of Injectable Agents to Overcome Hypoglycemia Risk, Barriers, and Clinical Inertia in Community-Dwelling Older Adults with Type 2 Diabetes Mellitus. Drugs Aging. 2019 12; 36(12):1083-1096.
    View in: PubMed
    Score: 0.090
  27. Interaction Between Type 2 Diabetes Prevention Strategies and Genetic Determinants of Coronary Artery Disease on Cardiometabolic Risk Factors. Diabetes. 2020 01; 69(1):112-120.
    View in: PubMed
    Score: 0.089
  28. Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program. Diabetes. 2019 12; 68(12):2337-2349.
    View in: PubMed
    Score: 0.089
  29. Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2019 11; 42(11):2098-2107.
    View in: PubMed
    Score: 0.088
  30. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019 07 13; 394(10193):131-138.
    View in: PubMed
    Score: 0.087
  31. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 07 13; 394(10193):121-130.
    View in: PubMed
    Score: 0.087
  32. Women relatives of Hispanic patients with type 2 diabetes are more prone to exhibit metabolic disturbances. Invest Clin. 1999 Jun; 40(2):127-42.
    View in: PubMed
    Score: 0.087
  33. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019 05 21; 170(10):682-690.
    View in: PubMed
    Score: 0.086
  34. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 08; 360(2):129-39.
    View in: PubMed
    Score: 0.084
  35. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care. 2018 08; 41(8):1672-1680.
    View in: PubMed
    Score: 0.081
  36. Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2017 07; 40(7):958-965.
    View in: PubMed
    Score: 0.075
  37. Activity and Sedentary Time 10 Years After a Successful Lifestyle Intervention: The Diabetes Prevention Program. Am J Prev Med. 2017 Mar; 52(3):292-299.
    View in: PubMed
    Score: 0.073
  38. Transcultural Endocrinology: Adapting Type-2 Diabetes Guidelines on a Global Scale. Endocrinol Metab Clin North Am. 2016 12; 45(4):967-1009.
    View in: PubMed
    Score: 0.072
  39. [Dyslipidemia and hyperinsulinemia in normoglycemic-obese relatives of patients with non-insulin dependent diabetes mellitus]. Invest Clin. 1995 Sep; 36(3):131-47.
    View in: PubMed
    Score: 0.067
  40. Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial. Diabetes Obes Metab. 2015 Oct; 17(10):949-55.
    View in: PubMed
    Score: 0.066
  41. The impact of lifestyle intervention on sedentary time in individuals at high risk of diabetes. Diabetologia. 2015 Jun; 58(6):1198-202.
    View in: PubMed
    Score: 0.065
  42. Impact of diagnosis of diabetes on health-related quality of life among high risk individuals: the Diabetes Prevention Program outcomes study. Qual Life Res. 2014 Feb; 23(1):75-88.
    View in: PubMed
    Score: 0.057
  43. Confirming glycemic status in the Diabetes Prevention Program: implications for diagnosing diabetes in high risk adults. J Diabetes Complications. 2013 Mar-Apr; 27(2):150-7.
    View in: PubMed
    Score: 0.055
  44. Strict glycemic control and mortality risk among US adults with type 2 diabetes. J Diabetes Complications. 2011 Sep-Oct; 25(5):289-91.
    View in: PubMed
    Score: 0.050
  45. Long work hours is associated with suboptimal glycemic control among US workers with diabetes. Am J Ind Med. 2011 May; 54(5):375-83.
    View in: PubMed
    Score: 0.049
  46. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14; 374(9702):1677-86.
    View in: PubMed
    Score: 0.045
  47. The Avandia debacle: methodology and practical importance of the findings. South Med J. 2007 Nov; 100(11):1062-3.
    View in: PubMed
    Score: 0.039
  48. Hyperglycemia and dyslipidemia of Isabela, Gal?pagos, Ecuador: A pilot study of cardiovascular risk factors in an Isolated Island community. Diabetes Res Clin Pract. 2017 Aug; 130:108-112.
    View in: PubMed
    Score: 0.019
  49. Diabetes in older adults. Diabetes Care. 2012 Dec; 35(12):2650-64.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.